ONCY Quote, Financials, Valuation and Earnings

Edesa Biotech, Inc. has a net margin of -- compared to Oncolytics Biotech, Inc.'s net margin of --. Oncolytics Biotech, Inc.'s return on equity of -635.07% beat Edesa Biotech, Inc.'s return on equity of -80.46%.

Oncolytics Biotech, Inc. has a consensus price target of $5.49, signalling upside risk potential of 459.36%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $10.33 which suggests that it could grow by 550.89%. Given that Edesa Biotech, Inc. has higher upside potential than Oncolytics Biotech, Inc., analysts believe Edesa Biotech, Inc. is more attractive than Oncolytics Biotech, Inc..

Oncolytics Biotech, Inc. has a beta of 0.880, which suggesting that the stock is 11.965% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.

Oncolytics Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oncolytics Biotech, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.

Oncolytics Biotech, Inc. quarterly revenues are --, which are smaller than Edesa Biotech, Inc. quarterly revenues of --. Oncolytics Biotech, Inc.'s net income of -$10.5M is lower than Edesa Biotech, Inc.'s net income of -$1.7M. Notably, Oncolytics Biotech, Inc.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oncolytics Biotech, Inc. is -- versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience Corp. has a net margin of -- compared to Oncolytics Biotech, Inc.'s net margin of -2178.51%. Oncolytics Biotech, Inc.'s return on equity of -635.07% beat Lexaria Bioscience Corp.'s return on equity of -147.19%.

Oncolytics Biotech, Inc. has a consensus price target of $5.49, signalling upside risk potential of 459.36%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $6.00 which suggests that it could grow by 376.19%. Given that Oncolytics Biotech, Inc. has higher upside potential than Lexaria Bioscience Corp., analysts believe Oncolytics Biotech, Inc. is more attractive than Lexaria Bioscience Corp..

Oncolytics Biotech, Inc. has a beta of 0.880, which suggesting that the stock is 11.965% less volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.221%.

Oncolytics Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oncolytics Biotech, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.

Oncolytics Biotech, Inc. quarterly revenues are --, which are smaller than Lexaria Bioscience Corp. quarterly revenues of $174K. Oncolytics Biotech, Inc.'s net income of -$10.5M is lower than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, Oncolytics Biotech, Inc.'s price-to-earnings ratio is -- while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oncolytics Biotech, Inc. is -- versus 28.57x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.

ProMIS Neurosciences, Inc. has a net margin of -- compared to Oncolytics Biotech, Inc.'s net margin of --. Oncolytics Biotech, Inc.'s return on equity of -635.07% beat ProMIS Neurosciences, Inc.'s return on equity of -348.3%.

Oncolytics Biotech, Inc. has a consensus price target of $5.49, signalling upside risk potential of 459.36%. On the other hand ProMIS Neurosciences, Inc. has an analysts' consensus of $221.55 which suggests that it could grow by 2803.72%. Given that ProMIS Neurosciences, Inc. has higher upside potential than Oncolytics Biotech, Inc., analysts believe ProMIS Neurosciences, Inc. is more attractive than Oncolytics Biotech, Inc..

Oncolytics Biotech, Inc. has a beta of 0.880, which suggesting that the stock is 11.965% less volatile than S&P 500. In comparison ProMIS Neurosciences, Inc. has a beta of -0.050, suggesting its less volatile than the S&P 500 by 105.015%.

Oncolytics Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProMIS Neurosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oncolytics Biotech, Inc. pays -- of its earnings as a dividend. ProMIS Neurosciences, Inc. pays out -- of its earnings as a dividend.

Oncolytics Biotech, Inc. quarterly revenues are --, which are smaller than ProMIS Neurosciences, Inc. quarterly revenues of --. Oncolytics Biotech, Inc.'s net income of -$10.5M is higher than ProMIS Neurosciences, Inc.'s net income of -$11.6M. Notably, Oncolytics Biotech, Inc.'s price-to-earnings ratio is -- while ProMIS Neurosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oncolytics Biotech, Inc. is -- versus -- for ProMIS Neurosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals, Inc. has a net margin of -- compared to Oncolytics Biotech, Inc.'s net margin of -867.29%. Oncolytics Biotech, Inc.'s return on equity of -635.07% beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.

Oncolytics Biotech, Inc. has a consensus price target of $5.49, signalling upside risk potential of 459.36%. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.19 which suggests that it could grow by 24.61%. Given that Oncolytics Biotech, Inc. has higher upside potential than Xenon Pharmaceuticals, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Xenon Pharmaceuticals, Inc..

Oncolytics Biotech, Inc. has a beta of 0.880, which suggesting that the stock is 11.965% less volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 1.027, suggesting its more volatile than the S&P 500 by 2.689%.

Oncolytics Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oncolytics Biotech, Inc. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Oncolytics Biotech, Inc. quarterly revenues are --, which are smaller than Xenon Pharmaceuticals, Inc. quarterly revenues of --. Oncolytics Biotech, Inc.'s net income of -$10.5M is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, Oncolytics Biotech, Inc.'s price-to-earnings ratio is -- while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oncolytics Biotech, Inc. is -- versus 465.45x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.